Mesa Laboratories Inc

NASDAQ MLAB

Download Data

Mesa Laboratories Inc Shareholders' Equity 5 year CAGR for the Trailing 12 Months (TTM) ending December 31, 2023: 30.23%

Mesa Laboratories Inc Shareholders' Equity 5 year CAGR is 30.23% for the Trailing 12 Months (TTM) ending December 31, 2023, a -7.29% change year over year. Shareholders' Equity is the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Mesa Laboratories Inc Shareholders' Equity for the Trailing 12 Months (TTM) ending December 31, 2022 was USD 387.20 M, a -2.30% change year over year.
  • Mesa Laboratories Inc Shareholders' Equity for the Trailing 12 Months (TTM) ending December 31, 2021 was USD 396.33 M, a -3.99% change year over year.
  • Mesa Laboratories Inc Shareholders' Equity for the Trailing 12 Months (TTM) ending December 31, 2020 was USD 412.80 M, a 76.28% change year over year.
  • Mesa Laboratories Inc Shareholders' Equity for the Trailing 12 Months (TTM) ending December 31, 2019 was USD 234.17 M, a 117.65% change year over year.
NASDAQ: MLAB

Mesa Laboratories Inc

CEO Mr. Gary M. Owens
IPO Date Jan. 25, 1995
Location United States
Headquarters 12100 West Sixth Avenue, Lakewood, CO, United States, 80228
Employees 698
Sector Technology
Industry Scientific & technical instruments
Description

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982

Similar companies

ITRI

Itron Inc

NA

NA

FTV

Fortive Corp

NA

NA

ESE

ESCO Technologies Inc

NA

NA

ST

Sensata Technologies Holding NV

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email